Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gossamer BioGOSS -8.02%16 Debt-to-Equity is -1.26 as of Mar. 2026. GuruFocus rates GOSS with a GF Score™ of 16/100. The stock has 5 warning signs investors should review. Among 966 Biotechnology companies, Gossamer Bio ranks worse than 103519.57% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Gossamer Bio's Debt-to-Equity or its related term are showing as below:
GOSS'
s Debt-to-Equity Range Over the Past 10 Years
Min: -32.45 Med: 0.43 Max: 18.69
Current: -1.26
During the past 10 years, the highest Debt-to-Equity Ratio of Gossamer Bio was 18.69. The lowest was -32.45. And the median was 0.43.
GOSS's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.16
vs GOSS: -1.26
Gossamer Bio (NAS:GOSS) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Gossamer Bio Debt-to-Equity Related Terms
Gossamer Bio Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Gossamer Bio's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GOSS vs ELTX, ACET, EDSA: Debt-to-Equity Comparison
For the Biotechnology subindustry, Gossamer Bio's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gossamer Bio Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gossamer Bio's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Gossamer Bio's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gossamer Bio (GOSS) has a Debt-to-Equity of -1.26 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Gossamer Bio and its competitors. According to the industry distribution chart, Gossamer Bio ranks #999999 out of 966 companies in the Biotechnology industry.
Is Gossamer Bio's Debt-to-Equity too high?
Gossamer Bio's current Debt-to-Equity is -1.26. Based on the distribution chart, Gossamer Bio ranks #999999 out of 966 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Gossamer Bio has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Gossamer Bio's Debt-to-Equity compare to ELTX and ACET?
According to the Biotechnology industry distribution chart, Gossamer Bio ranks #999999 out of 966 companies for Debt-to-Equity. This places Gossamer Bio in the lower half of its industry. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Gossamer Bio and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gossamer Bio's current Debt-to-Equity is -1.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gossamer Bio stock overvalued right now?
Gossamer Bio (GOSS) has a current Debt-to-Equity of -1.26. The current Debt-to-Equity is -1.26. Gossamer Bio's overall GF Score™ is 16/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Gossamer Bio (GOSS), the current Debt-to-Equity is -1.26 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).
16GF Score
Get the complete analysis for GOSS
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GOSS has been successfully added to your 
